Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Thumbnail

Feel the (heart) beat

An interactive dance project called 4Chambers includes choreography that depicts a cardiac arrest and video about heart attacks. The work, described in Studio 360, was inspired by a conversation with a cardiologist who encourages her patients to dance, which she calls “the perfect activity.”  

Societies offer go-to resource for PCI centers without surgical backup

PCI centers that don’t provide on-site surgical backup caught a break on March 17 with the publication of a paper that consolidates recommendations into a single document. “We tried to take everything that has been out there and put it all in one resource so people don’t have to hunt around,” lead author Gregory J. Dehmer, MD, told Cardiovascular Business.

Gender gap extends to treatment for acute coronary syndrome

Younger women with acute coronary syndrome may not receive care as quickly as men, a study published online March 17 in the e Canadian Medical Association Journal found. The study also found that women were less likely than men to get certain treatments for ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation MI (NSTEMI) or unstable angina. 

Boston Scientific receives CE Mark approval for REBEL platinum chromium coronary stent system

Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).

Boston Heart enables healthcare providers to better identify near-term risk of heart attack or stroke with launch of an important inflammation marker, myeloperoxidase (MPO)

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

Thumbnail

Building a Better Cath Lab Report

Wolters Kluwer

Creating the best cardiac cath lab procedure report is the first step to bettering patient care and maximizing reimbursement in this competitive and complex zone.

Thumbnail

Disappearing Act: From Coatings to Cage-free Coronaries

Biodegradable stents overcome some problems associated with other drug-eluting stents (DES), but advancements in newer durable polymers may give them a run for the money. 

Report: Cath lab steers scheduled patients through ED

An article by Bloomberg News claims that the cath lab at Mount Sinai Hospital in New York City has sent patients with previously scheduled appointments through its emergency department (ED), a practice that may allow for uninsured patients’ costs to be covered. The hospital has not been accused of any wrong-doing and hospital officials said they are reviewing issues related to the allegations.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.